Shopping Cart

No products in the cart.

Go to top

Novavax COVID-19 vaccine 90.4% effective in clinical trial, the company says

Novavax announced on Monday that its COVID-19 vaccine is over 90% overall effective and offers 100% protection against moderate and severe illness in a Phase 3 clinical trial. The company announced that it would file for FDA approval in the third quarter.

“Today Novavax took a step closer to meeting the critical and ongoing global public health need for additional COVID-19 vaccines,” said Stanley C. Erck, President and CEO of Novavax, in a statement. “These clinical results confirm that NVX-CoV2373 is extremely effective and provides complete protection against moderate and severe COVID-19 infections. Novavax continues to work hard to finalize our regulatory filings and deliver this vaccine, which is on a well understood and proven platform for a world that is still in dire need of vaccines. ”


This is an evolving story, please keep checking back for updates.

Leave Comments